4//SEC Filing
RONNEBERG AMY L 4
Accession 0000899243-18-018334
CIK 0001690585other
Filed
Jun 26, 8:00 PM ET
Accepted
Jun 27, 4:31 PM ET
Size
10.2 KB
Accession
0000899243-18-018334
Insider Transaction Report
Form 4
RONNEBERG AMY L
Director
Transactions
- Conversion
Common Stock
2018-06-25+593,611→ 593,611 total(indirect: See Footnote) - Conversion
Series B Preferred Stock
2018-06-25−1,287,100→ 0 total(indirect: See Footnote)→ Common Stock (498,107 underlying) - Conversion
Series C Preferred Stock
2018-06-25−246,781→ 0 total(indirect: See Footnote)→ Common Stock (95,504 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
- [F2]The shares are held directly by Be The Match BioTherapies, LLC ("Be the Match"). Ms. Ronneberg is President of Be The Match and disclaims beneficial ownership of such securities, except to the extent of her pecuniary interest therein, if any.
Documents
Issuer
Magenta Therapeutics, Inc.
CIK 0001690585
Entity typeother
Related Parties
1- filerCIK 0001380292
Filing Metadata
- Form type
- 4
- Filed
- Jun 26, 8:00 PM ET
- Accepted
- Jun 27, 4:31 PM ET
- Size
- 10.2 KB